Jeannette Ossewaarde-Van Norel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeannette Ossewaarde-Van Norel has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Aniki Rothova
Department of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
4 shared publicationsJoke H. de Boer
From the Department of Ophthalmology, University Medical Center Utrecht, Utrecht University, the Netherlands
3 shared publicationsRedmer van Leeuwen
3 shared publicationsSaskia M. Imhof
3 shared publicationsWilko Spiering
3 shared publications- Evianne L. de Groot
Department of Ophthalmology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 25 March 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 252, 45-58
Exploring Imaging Characteristics Associated With Disease Activity in Idiopathic Multifocal Choroiditis: A Multimodal Imaging Approach
- 25 March 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 252, 45-58
Open AccessExploring Imaging Characteristics Associated With Disease Activity in Idiopathic Multifocal Choroiditis: A Multimodal Imaging Approach
- Open Access
- 29 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 1047
Plasma Level of Pyrophosphate Is Low in Pseudoxanthoma Elasticum Owing to Mutations in the ABCC6 Gene, but It Does Not Correlate with ABCC6 Genotype
Background: Pseudoxanthoma elasticum (PXE), a monogenic disorder resulting in calcification affecting the skin, eyes and peripheral arteries, is caused by mutations in the ABCC6 gene, and is associated with low plasma inorganic pyrophosphate (PPi). It is unknown how ABCC6 genotype affects plasma PPi. Methods: We studied the association of ABCC6 genotype (192 patients with biallelic pathogenic ABCC6 mutations) and PPi levels, and its association with the severity of arterial and ophthalmological phenotypes. ABCC6 variants were classified as truncating or non-truncating, and three groups of the 192 patients were formed: those with truncating mutations on both chromosomes (n = 121), those with two non-truncating mutations (n = 10), and a group who had one truncating and one non-truncating ABCC6 mutation (n = 61). The hypothesis formulated before this study was that there was a negative association between PPi level and disease severity. Results: Our findings confirm low PPi in PXE compared with healthy controls (0.53 ± 0.15 vs. 1.13 ± 0.29 µM, p < 0.01). The PPi of patients correlated with increasing age (β: 0.05 µM, 95% CI: 0.03–0.06 per 10 years) and was higher in females (0.55 ± 0.17 vs. 0.51 ± 0.13 µM in males, p = 0.03). However, no association between PPi and PXE phenotypes was found. When adjusted for age and sex, no association between PPi and ABCC6 genotype was found. Conclusions: Our data suggest that the relationship between ABCC6 mutations and reduced plasma PPi may not be as direct as previously thought. PPi levels varied widely, even in patients with the same ABCC6 mutations, further suggesting a lack of direct correlation between them, even though the ABCC6 protein-mediated pathway is responsible for ~60% of this metabolite in the circulation. We discuss potential factors that may perturb the expected associations between ABCC6 genotype and PPi and between PPi and disease severity. Our findings support the argument that predictions of pathogenicity made on the basis of mutations (or on the structure of the mutated protein) could be misleading.
- 29 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 1047
Open AccessPlasma Level of Pyrophosphate Is Low in Pseudoxanthoma Elasticum Owing to Mutations in the ABCC6 Gene, but It Does Not Correlate with ABCC6 Genotype
Background: Pseudoxanthoma elasticum (PXE), a monogenic disorder resulting in calcification affecting the skin, eyes and peripheral arteries, is caused by mutations in the ABCC6 gene, and is associated with low plasma inorganic pyrophosphate (PPi). It is unknown how ABCC6 genotype affects plasma PPi. Methods: We studied the association of ABCC6 genotype (192 patients with biallelic pathogenic ABCC6 mutations) and PPi levels, and its association with the severity of arterial and ophthalmological phenotypes. ABCC6 variants were classified as truncating or non-truncating, and three groups of the 192 patients were formed: those with truncating mutations on both chromosomes (n = 121), those with two non-truncating mutations (n = 10), and a group who had one truncating and one non-truncating ABCC6 mutation (n = 61). The hypothesis formulated before this study was that there was a negative association between PPi level and disease severity. Results: Our findings confirm low PPi in PXE compared with healthy controls (0.53 ± 0.15 vs. 1.13 ± 0.29 µM, p < 0.01). The PPi of patients correlated with increasing age (β: 0.05 µM, 95% CI: 0.03–0.06 per 10 years) and was higher in females (0.55 ± 0.17 vs. 0.51 ± 0.13 µM in males, p = 0.03). However, no association between PPi and PXE phenotypes was found. When adjusted for age and sex, no association between PPi and ABCC6 genotype was found. Conclusions: Our data suggest that the relationship between ABCC6 mutations and reduced plasma PPi may not be as direct as previously thought. PPi levels varied widely, even in patients with the same ABCC6 mutations, further suggesting a lack of direct correlation between them, even though the ABCC6 protein-mediated pathway is responsible for ~60% of this metabolite in the circulation. We discuss potential factors that may perturb the expected associations between ABCC6 genotype and PPi and between PPi and disease severity. Our findings support the argument that predictions of pathogenicity made on the basis of mutations (or on the structure of the mutated protein) could be misleading.
- Open Access
- 11 January 2021
- Published by Elsevier in Ophthalmology Science
- Vol. 1 (1)
The Natural History of Bruch’s Membrane Calcification in Pseudoxanthoma Elasticum
- 11 January 2021
- Published by Elsevier in Ophthalmology Science
- Vol. 1 (1)
Open AccessThe Natural History of Bruch’s Membrane Calcification in Pseudoxanthoma Elasticum
- Open Access
- 1 December 2020
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 20
The efficacy of adalimumab in treating patients with central multifocal choroiditis
- 1 December 2020
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 20
Open AccessThe efficacy of adalimumab in treating patients with central multifocal choroiditis
- Open Access
- 20 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0240970
The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum
To assess the effect of the bisphosphonate etidronate on choroidal neovascular (CNV) activity in patients with pseudoxanthoma elasticum (PXE). This is an ancillary study in a single center, randomized, double-blind placebo-controlled trial (RCT) in which 74 patients with PXE were assigned to either one-year etidronate or placebo treatment. Spectral domain optical coherence tomography (SD-OCT) imaging and color fundus photography were performed every three months for one year and were systematically assessed on signs of CNV activity. In the etidronate group, 11 (30%) of the patients had CNV activity at baseline, compared to 25 (67%) of the patients in the placebo group (P = 0.005). The proportion of eyes with CNV activity during the study ranged from 18–33% in the etidronate group and 42–56% in the placebo group and no significant difference in improvement or worsening of CNV activity was found (P = 0.168). Using a generalized mixed model for repeated measures, there was a protective effect of etidronate in crude analysis (RR 0.86, 95% CI 0.75–0.98) that disappeared when adjusting for baseline CNV activity (RR 0.97, 95% CI 0.84–1.13). In this post-hoc RCT analysis we did not observe a protecting or deteriorating effect of etidronate on CNV activity in patients with PXE after adjustment for baseline CNV.
- 20 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0240970
Open AccessThe effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum
To assess the effect of the bisphosphonate etidronate on choroidal neovascular (CNV) activity in patients with pseudoxanthoma elasticum (PXE). This is an ancillary study in a single center, randomized, double-blind placebo-controlled trial (RCT) in which 74 patients with PXE were assigned to either one-year etidronate or placebo treatment. Spectral domain optical coherence tomography (SD-OCT) imaging and color fundus photography were performed every three months for one year and were systematically assessed on signs of CNV activity. In the etidronate group, 11 (30%) of the patients had CNV activity at baseline, compared to 25 (67%) of the patients in the placebo group (P = 0.005). The proportion of eyes with CNV activity during the study ranged from 18–33% in the etidronate group and 42–56% in the placebo group and no significant difference in improvement or worsening of CNV activity was found (P = 0.168). Using a generalized mixed model for repeated measures, there was a protective effect of etidronate in crude analysis (RR 0.86, 95% CI 0.75–0.98) that disappeared when adjusting for baseline CNV activity (RR 0.97, 95% CI 0.84–1.13). In this post-hoc RCT analysis we did not observe a protecting or deteriorating effect of etidronate on CNV activity in patients with PXE after adjustment for baseline CNV.
- Open Access
- 1 July 2020
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 9 (8) , 34
A Reflectivity Measure to Quantify Bruch's Membrane Calcification in Patients with Pseudoxanthoma Elasticum Using Optical Coherence Tomography
Purpose: Progressive calcification of Bruch's membrane (BM) causes considerable visual morbidity in patients with pseudoxanthoma elasticum (PXE). Since calcification is hyperreflective on optical coherence tomography (OCT), our aim was to measure BM calcification with OCT imaging. Methods: Case-control study with 45 patients with PXE under 40 years (range, 11–39) and 25 controls (range, 14–39). Spectralis HRA-OCT imaging consisted of seven macular B-scans with 250-µm spacing. Retinal segmentation was performed with the IOWA Reference Algorithms. MATLAB was used to extract and average z-axis reflectivity profiles. Layer reflectivities were normalized to the ganglion cell and inner plexiform layers. Both median and peak layer reflectivities were compared between patients with PXE and controls. The discriminative value of the retinal pigment epithelium (RPE)–BM peak reflectivity was analyzed using receiver operating characteristic analysis. Results: The reflectivity profile of patients with PXE differed from controls in the outer retinal layers. The normalized median RPE-BM reflectivity was 41.1 (interquartile range [IQR], 26.3–51.9) in patients with PXE, compared with 22.5 (IQR, 19.3–29.5) in controls (P = 2.09 × 10−3). The normalized RPE-BM peak reflectivity was higher in patients with PXE (67.5; IQR, 42.1–84.2) than in controls (32.7; IQR, 25.7–38.9; P = 2.43 × 10−5) and had a high discriminative value with an area under the curve of 0.85 (95% confidence interval, 0.76–0.95). In patients with PXE under 40 years, increasing age did not have a statistically significant effect on the RPE-BM peak reflectivity (patients under 20 years: 44.2 [IQR, 40.5–74.6]; 20–30 years: 66.0 [IQR, 45.1–83.8]; 30-40 years: 70.8 [IQR, 49.0–88.0], P = 0.47). Conclusions: BM calcification can be measured as increased RPE-BM reflectivity in young patients with PXE and has a high discriminative value. Translational Relevance: In patients with PXE, the OCT reflectivity of Bruch's membrane may be the first biomarker for Bruch's membrane calcification and a valuable ophthalmologic endpoint in clinical trials.
- 1 July 2020
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 9 (8) , 34
Open AccessA Reflectivity Measure to Quantify Bruch's Membrane Calcification in Patients with Pseudoxanthoma Elasticum Using Optical Coherence Tomography
Purpose: Progressive calcification of Bruch's membrane (BM) causes considerable visual morbidity in patients with pseudoxanthoma elasticum (PXE). Since calcification is hyperreflective on optical coherence tomography (OCT), our aim was to measure BM calcification with OCT imaging. Methods: Case-control study with 45 patients with PXE under 40 years (range, 11–39) and 25 controls (range, 14–39). Spectralis HRA-OCT imaging consisted of seven macular B-scans with 250-µm spacing. Retinal segmentation was performed with the IOWA Reference Algorithms. MATLAB was used to extract and average z-axis reflectivity profiles. Layer reflectivities were normalized to the ganglion cell and inner plexiform layers. Both median and peak layer reflectivities were compared between patients with PXE and controls. The discriminative value of the retinal pigment epithelium (RPE)–BM peak reflectivity was analyzed using receiver operating characteristic analysis. Results: The reflectivity profile of patients with PXE differed from controls in the outer retinal layers. The normalized median RPE-BM reflectivity was 41.1 (interquartile range [IQR], 26.3–51.9) in patients with PXE, compared with 22.5 (IQR, 19.3–29.5) in controls (P = 2.09 × 10−3). The normalized RPE-BM peak reflectivity was higher in patients with PXE (67.5; IQR, 42.1–84.2) than in controls (32.7; IQR, 25.7–38.9; P = 2.43 × 10−5) and had a high discriminative value with an area under the curve of 0.85 (95% confidence interval, 0.76–0.95). In patients with PXE under 40 years, increasing age did not have a statistically significant effect on the RPE-BM peak reflectivity (patients under 20 years: 44.2 [IQR, 40.5–74.6]; 20–30 years: 66.0 [IQR, 45.1–83.8]; 30-40 years: 70.8 [IQR, 49.0–88.0], P = 0.47). Conclusions: BM calcification can be measured as increased RPE-BM reflectivity in young patients with PXE and has a high discriminative value. Translational Relevance: In patients with PXE, the OCT reflectivity of Bruch's membrane may be the first biomarker for Bruch's membrane calcification and a valuable ophthalmologic endpoint in clinical trials.
- 1 April 2015
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 159 (4) , 690-697
Long-Term Visual Prognosis of Peripheral Multifocal Chorioretinitis
- 1 April 2015
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 159 (4) , 690-697
Long-Term Visual Prognosis of Peripheral Multifocal Chorioretinitis
- 1 August 2012
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 154 (2) , 233-239
Discrepancies Between Fluorescein Angiography and Optical Coherence Tomography in Macular Edema in Uveitis
- 1 August 2012
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 154 (2) , 233-239
Discrepancies Between Fluorescein Angiography and Optical Coherence Tomography in Macular Edema in Uveitis
- Open Access
- 14 February 2011
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 129 (2) , 158-162
Subfoveal Serous Retinal Detachment in Patients With Uveitic Macular Edema
Research from JAMA Ophthalmology — Subfoveal Serous Retinal Detachment in Patients With Uveitic Macular Edema
- 14 February 2011
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 129 (2) , 158-162
Open AccessSubfoveal Serous Retinal Detachment in Patients With Uveitic Macular Edema
Research from JAMA Ophthalmology — Subfoveal Serous Retinal Detachment in Patients With Uveitic Macular Edema
- 31 October 2010
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 19 (1) , 75-83
Clinical Review: Update on Treatment of Inflammatory Macular Edema
The aim of this review is to summarize the recent developments in the treatment of inflammatory macular edema (ME). Inflammatory ME represents a major cause of visual loss in uveitis and its adequate management is crucial for the maintenance of useful vision in patients with uveitis. Recent studies favor early treatment of inflammatory ME, even in patients with full visual acuity. After recapitulating the standard treatment modalities for inflammatory ME the authors address novel corticosteroid implants. They review the literature on the efficacy of anti-VEGF agents for inflammatory ME and point out their beneficial, but transient effects. Further, they present recent data on the value of systemic biologics in uveitic ME and evaluate the effectiveness of vitrectomy. Finally, they propose an algorithm for the treatment of inflammatory ME and point out that the individual risk–benefit ratio, especially with systemic immunosuppressive therapy, should always be considered.
- 31 October 2010
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 19 (1) , 75-83
Clinical Review: Update on Treatment of Inflammatory Macular Edema
The aim of this review is to summarize the recent developments in the treatment of inflammatory macular edema (ME). Inflammatory ME represents a major cause of visual loss in uveitis and its adequate management is crucial for the maintenance of useful vision in patients with uveitis. Recent studies favor early treatment of inflammatory ME, even in patients with full visual acuity. After recapitulating the standard treatment modalities for inflammatory ME the authors address novel corticosteroid implants. They review the literature on the efficacy of anti-VEGF agents for inflammatory ME and point out their beneficial, but transient effects. Further, they present recent data on the value of systemic biologics in uveitic ME and evaluate the effectiveness of vitrectomy. Finally, they propose an algorithm for the treatment of inflammatory ME and point out that the individual risk–benefit ratio, especially with systemic immunosuppressive therapy, should always be considered.